

Technology Advisory Committee A Interests Register

Topic: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane [ID3909]

Publication Date: 01/02/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Becky Pennington	Committee member	Financial	Becky has undertaken consultancy work funded by Roche (via the ABPI/office for health economics) and received a fee. This was in April 2022. The work was methodological relating the carers' HRQL and was not specific to any drug. The work was not related to breast cancer or trastuzumab emtansine.	-	03.10.2022	-	It was agreed her declaration would not prevent Becky from participating in discussions of this appraisal.
Holly Heath	Patient expert	Indirect financial	In the last 12 months Breast Cancer Now has received funding from the manufacturer Daiichi Sankyo and possible comparator company Roche either towards their living with secondary breast cancer online and face to face services	-	30.09.2022	-	It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
Professor Peter Schmid	Clinical expert	Indirect	Professor Schmid is conducting research on the use of pembrolizumab for	-	25.04.2022	-	It was agreed his declaration would not prevent Professor Peter

			other treatment indications (endometrial and other cervix cancer)..				Schmid from providing expert advice to the committee.